Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19
TORONTO, May 02, 2023 -- Revive Therapeutics Ltd. , a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today... | May 2, 2023
Michael Frank Therapeutics Ltd Psilocin Pharma Corp Safety Monitoring Board Bucillamine Phase Orphan Drug
Source: marketscreener.com